Clinical trials: Nephrectomy
Nephrectomy, Prostatectomy
Safety and Performance Assessment of a First Four Arms on Demand Open Robotic Solution for Assisted PN, RN and RP
The purpose of this clinical investigation was to evaluate the safety and performance of the Bitrack System and its corresponding ElectroSurgical Endoscopic (ESE) instruments and Non-ElectroSurgical Endoscopic (NESE) instruments…
- Trial name
- NCT06119568
- Testing
- Robot assisted laparoscopic Radical/simple nephrectomy (RN), Partial nephrectomy (PN) or Radical Prostatectomy (RP).
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- Rob Surgical Systems S.L.
Renal Cell Cancer
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy
This 2-arm study will evaluate the efficacy and safety of Avastin versus placebo in combination with Roferon as first-line treatment in participants with metastatic renal cell cancer (clear cell type) who have had nephrectomy.
- Trial name
- NCT00738530
- Testing
- Bevacizumab [Avastin], Interferon alfa 2a [Roferon]
- Where
- 104 sites in Australia, Belgium and 16 more
- Volunteers
- 649 people
- Sponsor
- Hoffmann-La Roche
Renal Cell Carcinoma
Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)
The purpose of this study is to evaluate the safety and efficacy of pembrolizumab (MK-3475) in the adjuvant treatment of adult participants who have undergone nephrectomy and have intermediate-high risk, high risk, or M1 no…
- Trial name
- NCT03142334
- Testing
- Pembrolizumab
- Where
- 251 sites in United States, Argentina and 19 more
- Volunteers
- 994 people
- Sponsor
- Merck Sharp & Dohme LLC
Excision of Kidney
An Evaluation of a Powered Vascular Stapler in Laparoscopic Nephrectomies and Nephroureterectomies
This prospective, randomized, controlled, multi-center study will collect and compare data from the surgeon's current standard of care stapler (for renal artery and renal vein transection) and powered vascular stapler
- Trial name
- NCT02807376
- Testing
- Surgeon's 'standard of care' stapler, Ethicon Powered Vascular Stapler
- Where
- United States
- Volunteers
- 270 people
- Sponsor
- Ethicon Endo-Surgery
Renal Cell Carcinoma, Metastatic
Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC)
The purpose of this study is to compare tumor response, progression free survival (PFS) and overall survival (OS) in newly diagnosed mRCC patients treated with Intuvax (INN: ilixadencel) pre-nephrectomy followed by Sunitinib…
- Trial name
- MERECA (NCT02432846)
- Testing
- Intuvax (INN: ilixadencel), Sunitinib
- Where
- 28 sites in United States, Czechia and 7 more
- Volunteers
- 88 people
- Sponsor
- Mendus
Renal Cell Carcinoma (RCC), Cancer
A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)
This randomized Phase III study is to evaluate whether pazopanib compared with placebo can prevent or delay recurrence of kidney cancer in patients with moderately high or high risk of developing recurrence after undergoing…
- Trial name
- PROTECT (NCT01235962)
- Testing
- pazopanib
- Where
- 312 sites in United States, Argentina and 24 more
- Volunteers
- 1,538 people
- Sponsor
- Novartis Pharmaceuticals
Nephrectomy
HYbrid RObotic Surgery in Urology
The HYbrid RObotic Surgery in urology (HYROS) study is an early feasibility clinical investigation of a new medical device under the commercial name of Bitrack System.
- Trial name
- HYROS (NCT05864040)
- Testing
- Bitrack System-assisted laparoscopic radical/simple nephrectomy
- Where
- Spain
- Volunteers
- 3 people
- Sponsor
- Rob Surgical Systems S.L.
Renal Cell Carcinoma
A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
This is a Phase III, multicenter, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of atezolizumab versus placebo in participants with RCC who are at high risk of disease recurrence following…
- Trial name
- IMmotion010 (NCT03024996)
- Testing
- Atezolizumab
- Where
- 186 sites in United States, Argentina and 26 more
- Volunteers
- 778 people
- Sponsor
- Hoffmann-La Roche
Clear Cell Renal Cell Carcinoma
Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma
The study will evaluate the clinical activity of sitravatinib in combination with nivolumab in patients with locally-advanced clear cell renal cell carcinoma (ccRCC) in the neoadjuvant setting prior to nephrectomy.
- Trial name
- NCT03680521
- Testing
- Sitravatinib, Nivolumab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Mirati Therapeutics Inc.
Renal Cell Carcinoma
Retrospective Study on Referral Patterns for High Risk Patients Post Nephrectomy
This study aims at estimating the proportion of patients diagnosed with locoregional renal cell carcinoma who are at high risk for recurrence following nephrectomy, describe referral patterns, and characterize treatment in this…
- Trial name
- NCT04309617
- Testing
- nephrectomy
- Where
- United States
- Volunteers
- 618 people
- Sponsor
- Pfizer
Carcinoma, Adenocarcinoma
Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer
To estimate the difference in efficacy and safety of bevacizumab and RAD001 compared to bevacizumab and interferon alfa-2a for first-line treatment of patients with metastatic carcinoma of the kidney.
- Conditions
- Carcinoma, Adenocarcinoma, Renal Cell, Nephroid Carcinoma
- Trial name
- NCT00719264
- Testing
- RAD001(everolimus), interferon alfa-2a, bevacizumab
- Where
- 109 sites in United States, Belgium and 19 more
- Volunteers
- 365 people
- Sponsor
- Novartis Pharmaceuticals
Carcinoma, Renal Cell
A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney
The purpose of this study is to determine whether nivolmab alone or the combination of nivolumab and ipilimumab versus placebo, is safe and effective for delaying or preventing recurrence of cancer in participants who have…
- Trial name
- CheckMate 914 (NCT03138512)
- Testing
- nivolumab, ipilimumab
- Where
- 200 sites in United States, Argentina and 23 more
- Volunteers
- 1,641 people
- Sponsor
- Bristol-Myers Squibb